“…Furthermore, the K-agonist response appears to be specific since a 8-opioid agonist elicited similar effects in Brattleboro and Long-Evans rats, and the &-agonist pressor response was not significantly altered by the AVP antagonist, but was completely blocked by phenoxybenzamine. The possibility that the differential action of U50488H in Brattleboro and Long-Evans rats and the AVP antagonist blockade may be explained by central autonomic effects of AVP in the nucleus tractus solitarii (Matsuguchi, Sharali, Gordon, Johnson & Schmid, 1982;Pittman, Lawrence & McLean, 1982) cannot be ruled out, but such action appears unlikely in view of the observation that the cardiovascular response to centrally administered AVP is not dependent upon AVP release from the pituitary (Pittman et al 1982) and the demonstration that the dose of AVP antagonist which blocked the K-agonist pressor response by approximately 50 % has been shown previously (Kruszynski, Lammek, Manning, Seto, Haldar & Sawyer, 1980) Zerbe & Kopin, 1984), and in the development of pressor responses (Hatzimkolaou, Gavras, Brunner & Gavras, 1981;Zukowska-Grojec, Bayorh, Zerbe, Palkovits & Kopin, 1983). Definitive evidence for a vasoconstrictor action ofAVP in the present study is lacking, but the results ofthe phenoxybenzamine experiments clearly indicate that sympathetic activation is not involved in the development of the U50488H-induced response.…”